Monitoring Biomarkers After Pediatric Heart Surgery: A New Paradigm on the Horizon

Artificial Organs

Volumn 37, Issue 1, 2013, Pages 10-15

  Aĝirbaşli, Mehmet ^a   Ündar, Akif ^b  

^a MARMARA UNIVERSITY   (Turkey)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Biomarkers; Cardiopulmonary bypass; Congenital heart disease; Outcomes; Pediatric heart surgery

Indexed keywords

CARDIOLOGY; DISEASES; HEART; PEDIATRICS; RISK ASSESSMENT; SURGERY;

ADULT PATIENTS; CARDIOPULMONARY BYPASS; CARDIOVASCULAR DISEASE; CONGENITAL HEART DISEASE; OUTCOME; PEDIATRIC HEART SURGERIES; REYNOLDS; RISK FACTORS; RISK SCORING; SCORING SYSTEMS;

BIOMARKERS;

BIOLOGICAL MARKER; C REACTIVE PROTEIN; COLLAGEN TYPE 3; COMPLEMENT COMPONENT C3; CREATINE KINASE BB; CREATINE KINASE MB; FATTY ACID BINDING PROTEIN; FIBRINOGEN; GELATINASE A; GELATINASE B; GLIAL FIBRILLARY ACIDIC PROTEIN; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; MYOGLOBIN; NEUROFILAMENT PROTEIN; NEURON SPECIFIC ENOLASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREGNANCY ASSOCIATED PLASMA PROTEIN A; PROTEIN S100B; SERUM AMYLOID A; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR; TROPONIN I; TROPONIN T; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN C;

CARDIOPULMONARY BYPASS; CARDIOVASCULAR DISEASE; CHILD CARE; CONGENITAL HEART DISEASE; HEART MUSCLE INJURY; HEART SURGERY; HEMODILUTION; HEMOSTASIS; HUMAN; MORBIDITY; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PATIENT MONITORING; PEDIATRIC SURGERY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SURGICAL MORTALITY;

EID: 84872369866     PISSN: 0160564X     EISSN: 15251594     Source Type: Journal    
DOI: 10.1111/j.1525-1594.2012.01573.x     Document Type: Review

References (40)

1. Moller J. Prevalence and incidence of cardiac malformation. In: Moller JH, ed. Perspectives in Pediatric Cardiology: Surgery of Congenital Heart Disease: Pediatric Cardiac Care Consortium, 1984-1995. Armonk, NY: Futura Publishing, 1998;19-26.
2. Reller MD, Strickland MJ, Riehle-Colarusso T, Mahle WT, Correa A. Prevalence of congenital heart defects in metropolitan Atlanta, 1998-2005. J Pediatr 2008;153:807-813.
3. Warnes CA, Liberthson R, Danielson GK, etal. Task force 1: the changing profile of congenital heart disease in adult life. J Am Coll Cardiol 2001;37:1170-1175.
4. Williams RG, Pearson GD, Barst RJ, etal.; National Heart, Lung, and Blood Institute Working Group on research in adult congenital heart disease. Report of the National Heart, Lung, and Blood Institute Working Group on research in adult congenital heart disease. J Am Coll Cardiol 2006;47:701-707.
5. Jenkins KJ. Risk adjustment for congenital heart surgery: the RACHS-1 method. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 2004;7:180-184.
6. Domico M, Checchia PA. Biomonitors of cardiac injury and performance: B-type natriuretic peptide and troponin as monitors of hemodynamics and oxygen transport balance. Pediatr Crit Care Med 2011;12(4 Suppl.):S33-42.
7. Maar SP. Searching for the Holy Grail: a review of markers of tissue perfusion in pediatric critical care. Pediatr Emerg Care 2008;24:883-887.
8. Agirbaşli M, Nguyen ML, Win K, etal. Inflammatory and hemostatic response to cardiopulmonary bypass in pediatric population: feasibility of seriological testing of multiple biomarkers. Artif Organs 2010;34:987-995.
9. Pinto N, Dolan ME. Clinically relevant genetic variations in drug metabolizing enzymes. Curr Drug Metab 2011;12:487-497.
10. Aran K, Fok A, Sasso LA, etal. Microfiltration platform for continuous blood plasma protein extraction from whole blood during cardiac surgery. Lab Chip 2011;11:2858-2868.
11. Sasso LA, Ündar A, Zahn JD. Autonomous magnetically actuated continuous flow microimmunofluorocytometry assay. Microfluid Nanofluidics 2010;9:253-265.
12. Umstead TM, Lu CK, Freeman WM, etal. The kinetics of cardiopulmonary bypass: a dual-platform proteomics study of plasma biomarkers in pediatric patients undergoing cardiopulmonary bypass. Artif Organs 2012;36:E1-20.
13. Jenkins KJ, Gauvreau K. Center-specific differences in mortality: preliminary analyses using the risk adjustment in congenital heart surgery (RACHS-1) method. J Thorac Cardiovasc Surg 2002;124:97-104.
14. Jonas RA. Review of current research at Boston Children's Hospital. Ann Thorac Surg 1993;56:1467-1472.
15. Adams JE 3rd. Clinical application of markers of cardiac injury: basic concepts and new considerations. Clin Chim Acta 1999;284:127-134.
16. Adams JE 3rd, Abendschein DR, Jaffe AS. Biochemical markers of myocardial injury. Is MB creatine kinase the choice for the 1990s? Circulation 1993;88:750-763.
17. Adams JE 3rd, Bodor GS, Davila-Roman VG, etal. A marker with high specificity for cardiac injury. Circulation 1993;88:101-106.
18. O'Connor RE, Brady W, Brooks SC, etal. Part 10: acute coronary syndromes: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010;122(Suppl. 3):S787-817.
19. Hasegawa T, Yoshimura N, Oka S, Ootaki Y, Toyoda Y, Yamaguchi M. Evaluation of heart fatty acid-binding protein as a rapid indicator for assessment of myocardial damage in pediatric cardiac surgery. J Thorac Cardiovasc Surg 2004;127:1697-1702.
20. Rizzo G, Silvestri E, Capponi A, etal. Histomorphometric characteristics of first trimester chorionic villi in pregnancies with low serum pregnancy-associated plasma protein-A levels: relationship with placental three-dimensional power doppler ultrasonographic vascularization. J Matern Fetal Neonatal Med 2011;24:253-257.
21. Lund J, Wittfooth S, Qin QP, etal. Free versus total pregnancy-associated plasma protein A (PAPP-A) as a predictor of 1-year outcome in patients presenting with non-ST-elevation acute coronary syndrome. Clin Chem 2010;56:1158-1165.
22. Baldus S, Heeschen C, Meinertz T, etal.; CAPTURE Investigators. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003;108:1440-1445.
23. Creighton DE, Robertson CM, Sauve RS, etal. Neurocognitive, functional, and health outcomes at 5 years of age for children after complex cardiac surgery at 6 weeks of age or younger. Pediatrics 2007;120:e478-486.
24. Majnemer A, Limperopoulos C, Shevell M, Rosenblatt B, Rohlicek C, Tchervenkov C. Long-term neuromotor outcome at school entry of infants with congenital heart defects requiring open-heart surgery. J Pediatr 2006;148:72-77.
25. Andropoulos DB, Hunter JV, Nelson DP, etal. Brain immaturity is associated with brain injury before and after neonatal cardiac surgery with high-flow bypass and cerebral oxygenation monitoring. J Thorac Cardiovasc Surg 2010;139:543-556.
26. Ramaswamy V, Horton J, Vandermeer B, Buscemi N, Miller S, Yager J. Systematic review of biomarkers of brain injury in term neonatal encephalopathy. Pediatr Neurol 2009;40:215-226.
27. Schmitt B, Bauersfeld U, Schmid ER, etal. Serum and CSF levels of neuron-specific enolase (NSE) in cardiac surgery with cardiopulmonary bypass: a marker of brain injury? Brain Dev 1998;20:536-539.
28. Lardner D, Davidson A, McKenzie I, Cochrane A. Delayed rises in serum S100B levels and adverse neurological outcome in infants and children undergoing cardiopulmonary bypass. Paediatr Anaesth 2004;14:495-500.
29. Siman R, Toraskar N, Dang A, etal. A panel of neuron-enriched proteins as markers for traumatic brain injury in humans. J Neurotrauma 2009;26:1867-1877.
30. Siman R, Roberts VL, McNeil E, etal. Biomarker evidence for mild central nervous system injury after surgically-induced circulation arrest. Brain Res 2008;1213:1-11.
31. Papa L, Akinyi L, Liu MC, etal. Ubiquitin C-terminal hydrolase is a novel biomarker in humans for severe traumatic brain injury. Crit Care Med 2010;38:138-144.
32. Su X, Ündar A. Brain protection during pediatric cardiopulmonary bypass. Artif Organs 2010;34:E91-102.
33. Agirbasli M. Pivotal role of plasminogen-activator inhibitor 1 in vascular disease. Int J Clin Pract 2005;59:102-106.
34. Chandler WL, Trimble SL, Loo SC, Mornin D. Effect of PAI-1 levels on the molar concentrations of active tissue plasminogen activator (t-PA) and t-PA/PAI-1 complex in plasma. Blood 1990;76:930-937.
35. Knottnerus IL, Govers-Riemslag JW, Hamulyak K, etal. Endothelial activation in lacunar stroke subtypes. Stroke 2010;41:1617-1622.
36. Lumpkins KM, Bochicchio GV, Keledjian K, Simard JM, McCunn M, Scalea T. Glial fibrillary acidic protein is highly correlated with brain injury. J Trauma 2008;65:778-782.
37. Schiff L, Hadker N, Weiser S, Rausch C. A literature review of the feasibility of glial fibrillary acidic protein as a biomarker for stroke and traumatic brain injury. Mol Diagn Ther 2012;16:79-92.
38. Savage WJ, Barron-Casella E, Fu Z, etal. Plasma glial fibrillary acidic protein levels in children with sickle cell disease. Am J Hematol 2011;86:427-429.
39. Akçevin A, Alkan-Bozkaya T, Qiu F, Undar A. Evaluation of perfusion modes on vital organ recovery and thyroid hormone homeostasis in pediatric patients undergoing cardiopulmonary bypass. Artif Organs 2010;34:879-884.
40. Furukawa T, Murakami T, Ueno M, Takeda A, Yakuwa S, Yamazawa H. The cause of B-type natriuretic peptide elevation and the dose-dependent effect of angiotensin-converting enzyme inhibitor on patients late after tetralogy of Fallot repair. Pediatr Cardiol 2012;33:264-271.